A randomised, double ‐blind, placebo‐controlled trial of metformin on myocardial efficiency in insulin‐resistant chronic heart failure patients without diabetes
ConclusionMetformin treatment in non ‐diabetic HFrEF patients improved myocardial efficiency by reducing myocardial oxygen consumption. Measurement of circulating metformin levels differentiated responders from non‐responders. These energy‐sparing effects of metformin encourage further large‐scale investigations in heart failur e patients without diabetes.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Anders Hostrup Larsen,
Niels Jessen,
Helene N ørrelund,
Lars Poulsen Tolbod,
Hendrik Johannes Harms,
Søren Feddersen,
Flemming Nielsen,
Kim Brøsen,
Nils Henrik Hansson,
Jørgen Frøkiær,
Steen Hvitfeldt Poulsen,
Jens Sörensen,
Henrik Wigg Tags: Research Article Source Type: research
More News: Cardiology | Diabetes | Endocrinology | Fortamet | Heart | Heart Failure | Insulin | Metformin | PET Scan | Sports Medicine | Stroke | Study